Stock SUVENPHAR SUVEN PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Suven Pharmaceuticals Limited Bombay S.E.

Equities

SUVENPHAR

INE03QK01018

Market Closed - Bombay S.E.
Other stock markets
 06:00:53 2024-07-12 am EDT 		5-day change 1st Jan Change
848.8 INR -0.81% Intraday chart for Suven Pharmaceuticals Limited +4.15% +16.88%
Jun. 19 Transcript : Sapala Organics Private Limited, Suven Pharmaceuticals Limited - M&A Call
Jun. 14 Suven Pharmaceuticals to Acquire 67.5% Stake in Sapala Organics MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 64.49 times its estimated earnings per share for the ongoing year.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SUVEN PHARMACEUTICALS LIMITED Stock Suven Pharmaceuticals Limited
+16.88% 2.6B
D-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 841B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 625B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 360B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 327B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.87% 300B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 242B
B+
NOVARTIS AG Stock Novartis AG
+17.90% 227B
B-
AMGEN INC. Stock Amgen Inc.
+14.86% 174B
C+
PFIZER, INC. Stock Pfizer, Inc.
+0.45% 162B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SUVENPHAR Stock
  4. SUVENPHAR Stock
  5. Ratings Suven Pharmaceuticals Limited